CHEK2 and breast cancer: On the other hand, incorporating PRS into BC risk estimation may help identify 30% of CHEK2 and nearly half of ATM carriers below the 20% lifetime risk threshold, suggesting the addition of PRS may prevent over screening and enable more personalized risk management approaches [175].